Details for Patent: 8,835,443
✉ Email this page to a colleague
Which drugs does patent 8,835,443 protect, and when does it expire?
Patent 8,835,443 protects TAFINLAR and MEKINIST and is included in four NDAs.
Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty patent family members in twenty-eight countries.
Summary for Patent: 8,835,443
| Title: | Pyrimidine compound and medical use thereof |
| Abstract: | The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I] ##STR00001## wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist. |
| Inventor(s): | Kawasaki; Hisashi (Takatsuki, JP), Abe; Hiroyuki (Takatsuki, JP), Hayakawa; Kazuhide (Takatsuki, JP), Iida; Tetsuya (Takatsuki, JP), Kikuchi; Shinichi (Takatsuki, JP), Yamaguchi; Takayuki (Takatsuki, JP), Nanayama; Toyomichi (Takatsuki, JP), Kurachi; Hironori (Takatsuki, JP), Tamaru; Masahiro (Takatsuki, JP), Hori; Yoshikazu (Takatsuki, JP), Takahashi; Mitsuru (Takatsuki, JP), Yoshida; Takayuki (Yokohama, JP), Sakai; Toshiyuki (Kyoto, JP) |
| Assignee: | Japan Tobacco Inc. (Tokyo, JP) |
| Application Number: | 12/626,443 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,835,443
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-002 | May 29, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Novartis | MEKINIST | trametinib dimethyl sulfoxide | SOLUTION;ORAL | 217513-001 | Mar 16, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Novartis | TAFINLAR | dabrafenib mesylate | TABLET, FOR SUSPENSION;ORAL | 217514-001 | Mar 16, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,835,443
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2004-174770 | Jun 11, 2004 |
| Japan | 2004-327111 | Nov 10, 2004 |
International Family Members for US Patent 8,835,443
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1761528 | ⤷ Sign Up | C300701 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1761528 | ⤷ Sign Up | PA2014039 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1761528 | ⤷ Sign Up | CA 2014 00055 | Denmark | ⤷ Sign Up |
| European Patent Office | 1761528 | ⤷ Sign Up | 14C0083 | France | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
